THERAPEUTIC APPLICATIONS

• Rheumatoid arthritis
• Possibly other autoimmune diseases, such as, IBD, Crohn’s Disease, Ulcerative Colitis, Atherosclerosis, etc.

EFFICACY

• In the adjuvant induced arthritis model in rats, SNS, dosed orally, reduces dorsoplantar swelling in a dose dependent manner.
• More significantly, SNS also displays dose dependent bone sparing activity.
  • Dose dependent reductions in:
    Joint space narrowing
    • Bone erosion
    • Osteoporosis
    • Periosteal bone formation.
• SNS outperforms both methotrexate and Remicade in this model.

SAFETY

• SNS displays a benign safety profile in preliminary tox studies.
  • No effects on general health, body weight, serum chemistries.
  • Gross organ exam normal.

MECHANISM OF ACTION

• SNS works early in the inflammatory cascade, hence inhibiting the action of many downstream cytokines.

OTHER FEATURES

• SNS (& analogs) has solid IP protection.
• SNS synthesis is straightforward and inexpensive.
• SNS is highly water soluble.
• There is scope for more SAR on SNS.

Download original PDF